Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy.

"Selim T. Koseoglu, MD, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Financial Disclosures : Selim T. Koseoglu, MD, has provided consulting support to BioMarin Pharmaceutical Inc., and received an honorarium for travel as a poster presenter at the 2007 ACMG meeting, Nashville, USA. Paul Harmatz, MD, has provided consulting support to BioMarin Pharmaceutical Inc., received an honorarium for travel as symposium speaker, and participated as PI in the clinical trials for Naglazyme approval. Sean Turbeville, PhD, is an employee and stockholder of BioMarin Pharmaceutical Inc., Novato, California. Helen Nicely, PhD, is an employee and stockholder of BioMarin Pharmaceutical Inc., Novato, California."